Adaptive biotechnologies stock.

Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …

Adaptive biotechnologies stock. Things To Know About Adaptive biotechnologies stock.

Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year. Of the 191 institutional investors that purchased Adaptive Biotechnologies stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARK Investment Management LLC ($6.79M), Sumitomo Mitsui Trust Holdings Inc. ($4.54M), Nikko Asset Management Americas Inc. ($3.11M), …Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive BiotechnologiesNov 30, 2023 · Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ... Adaptive Biotechnologies Corp. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:51 p.m. EST Delayed quote $ 4.2000 -0.17 -3.89% After Hours Volume: 4.47K Advanced...

At present, SG Americas Securities LLC holds a total of 76,854 shares of Adaptive Biotechnologies Co., compared to its previous ownership of 28,962 shares. The acquisition of an additional 47,892 shares during the first quarter highlights the firm’s belief in the long-term prospects and value of Adaptive Biotechnologies’ stock.

Dec 1, 2023 · A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.The institutional investor acquired 53,400 shares of the company’s stock, corresponding to a value of approximately $472,000. Adaptive Biotechnologies Co., listed on NASDAQ under the symbol ADPT, opened at $6.17 on Tuesday. Over the past year, its stock has ranged between a low of $5.96 and a high of $10.79.Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQ

Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...

Mar 9, 2023 · Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ... Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the …Find the latest Institutional Holdings data for Adaptive Biotechnologies Corporation Common Stock (ADPT) at Nasdaq.com.ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT.

ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …Adaptive Biotechnologies. Another stock that saw a Wall Street firm lower its price target after offering up an earnings report this month is Adaptive Biotechnologies. The immune-system genetic ...Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.

Adaptive’s layoffs come as a hot biotech IPO market during 2021 cools down and biotech stock values decline. One key biotech index fund, the SPDR S&P Biotech ETF (XBI), is down about 50% from ...

Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ...Adaptive Biotechnologies is a biotechnology company that develops products based on the adaptive immune system. The web page provides stock …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS. Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …4.3500. -0.1600. -3.55%. SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... ... stock price by the number of shares outstanding. Adaptive Biotechnologies market cap as of December 01, 2023 is $0.63B. Compare ADPT With Other Stocks ...Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.35) to ($1.10) per share. Adaptive Biotechnologies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 13th, 2024 based off prior year's report dates. Read More.

Nov 29, 2023 · Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

On November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ...Adaptive Biotechnologies Corp Follow Share $4.62 After Hours: $4.62 (0.00%) 0.00 Closed: Nov 29, 4:18:17 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to AbbVie Inc $138.50 ABBV0.0072%... Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... 2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ...The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price. With Adaptive Biotechnologies stock trading at $4.15 per share, the total value of Adaptive Biotechnologies stock (market capitalization) is $600.28M. Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years …May 26, 2023 · The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ... Mar 31, 2023 · As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ... You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued. Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …

Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Adaptive Biotechnologies Corp (NASDAQ: ADPT)’s stock price has soared by 3.44 in relation to previous closing price of 4.03. Nevertheless, the company has seen a gain of 18.77% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, […]Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Instagram:https://instagram. what is the best health insurance in njhow to choose a forex brokerstarlink investment3d printing etf SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ... etf consumer staplesschd fund BeiGene Ltd. Stock Performance and Financial Outlook: November 2023 Analysis. On November 7, 2023, BeiGene Ltd. (BGNE) experienced some fluctuations in its stock performance. The previous day’s close was recorded at $196.15, and the stock opened at $194.08. Throughout the day, the stock traded within a range of $194.08 to $197.57.So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%. micron memory Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.